95 related articles for article (PubMed ID: 9548959)
41. Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes.
Rossier O; Abuin L; Fanelli F; Leonardi A; Cotecchia S
Mol Pharmacol; 1999 Nov; 56(5):858-66. PubMed ID: 10531388
[TBL] [Abstract][Full Text] [Related]
42. Ligand design for alpha(1) adrenoceptors.
Bremner JB; Griffith R; Coban B
Curr Med Chem; 2001 May; 8(6):607-20. PubMed ID: 11281844
[TBL] [Abstract][Full Text] [Related]
43. In situ salt screening--a useful technique for discovery support and preformulation studies.
Tong WQ; Whitesell G
Pharm Dev Technol; 1998 May; 3(2):215-23. PubMed ID: 9653759
[TBL] [Abstract][Full Text] [Related]
44. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions.
Lapinsh M; Prusis P; Gutcaits A; Lundstedt T; Wikberg JE
Biochim Biophys Acta; 2001 Feb; 1525(1-2):180-90. PubMed ID: 11342268
[TBL] [Abstract][Full Text] [Related]
45. Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity.
Porter JE; Perez DM
J Biol Chem; 1999 Dec; 274(49):34535-8. PubMed ID: 10574914
[TBL] [Abstract][Full Text] [Related]
46. Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes.
Cavalli A; Fanelli F; Taddei C; De Benedetti PG; Cotecchia S
FEBS Lett; 1996 Dec; 399(1-2):9-13. PubMed ID: 8980109
[TBL] [Abstract][Full Text] [Related]
47. Modeling and mutagenesis of the human alpha 1a-adrenoceptor: orientation and function of transmembrane helix V sidechains.
Wetzel JM; Salon JA; Tamm JA; Forray C; Craig D; Nakanishi H; Cui W; Vaysse PJ; Chiu G; Weinshank RL; Hartig PR; Branchek TA; Gluchowski C
Recept Channels; 1996; 4(3):165-77. PubMed ID: 9014240
[TBL] [Abstract][Full Text] [Related]
48. Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling.
Greasley PJ; Fanelli F; Scheer A; Abuin L; Nenniger-Tosato M; DeBenedetti PG; Cotecchia S
J Biol Chem; 2001 Dec; 276(49):46485-94. PubMed ID: 11585821
[TBL] [Abstract][Full Text] [Related]
49. Quantitative structure-activity relationship study of new potent and selective antagonists at the 5-HT(1A) and adrenergic alpha(1d) receptors: Derivatives of spiroethyl phenyl(substituted)piperazine.
Sharma BK; Singh P; Sharma S
J Enzyme Inhib Med Chem; 2006 Oct; 21(5):601-7. PubMed ID: 17194034
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanisms involved in the activation and regulation of the alpha 1-adrenergic receptor subtypes.
Cotecchia S; Scheer A; Diviani D; Fanelli F; De Benedetti PG
Farmaco; 1998 Apr; 53(4):273-7. PubMed ID: 9658585
[TBL] [Abstract][Full Text] [Related]
51. Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.
Wetzel JM; Miao SW; Forray C; Borden LA; Branchek TA; Gluchowski C
J Med Chem; 1995 May; 38(10):1579-81. PubMed ID: 7752182
[No Abstract] [Full Text] [Related]
52. Prediction of selectivity of alpha1-adrenergic antagonists by counterpropagation neural network (CP-ANN).
Eric S; Solmajer T; Zupan J; Novic M; Oblak M; Agbaba D
Farmaco; 2004 May; 59(5):389-95. PubMed ID: 15120318
[TBL] [Abstract][Full Text] [Related]
53. Selective alpha-1a adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity.
Patane MA; DiPardo RM; Price RP; Chang RS; Ransom RW; O'Malley SS; Di Salvo J; Bock MG
Bioorg Med Chem Lett; 1998 Sep; 8(18):2495-500. PubMed ID: 9873568
[TBL] [Abstract][Full Text] [Related]
54. Molecular mechanisms of ligand binding and activation in alpha 1-adrenergic receptors.
Perez DM; Hwa J; Zhao MM; Porter J
Adv Pharmacol; 1998; 42():398-403. PubMed ID: 9327924
[No Abstract] [Full Text] [Related]
55. Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Vistoli G; Pedretti A; Villa L; Testa B
J Med Chem; 2005 Jul; 48(15):4947-52. PubMed ID: 16033273
[TBL] [Abstract][Full Text] [Related]
56. The alpha 1a and alpha 1b-adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action.
Cotecchia S; Rossier O; Fanelli F; Leonardi A; De Benedetti PG
Pharm Acta Helv; 2000 Mar; 74(2-3):173-9. PubMed ID: 10812955
[TBL] [Abstract][Full Text] [Related]
57. Correlated mutations and subtype specificity in the adrenergic receptor.
Gouldson PR; Bywater RP; Reynolds CA
Biochem Soc Trans; 1997 Aug; 25(3):434S. PubMed ID: 9388658
[No Abstract] [Full Text] [Related]
58. The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function.
Lopez-Gimenez JF; Canals M; Pediani JD; Milligan G
Mol Pharmacol; 2007 Apr; 71(4):1015-29. PubMed ID: 17220353
[TBL] [Abstract][Full Text] [Related]
59. Phenylacetamides as selective alpha-1A adrenergic receptor antagonists.
Patane MA; DiPardo RM; Newton RC; Price RP; Broten TP; Chang RS; Ransom RW; Di Salvo J; Nagarathnam D; Forray C; Gluchowski C; Bock MG
Bioorg Med Chem Lett; 2000 Aug; 10(15):1621-4. PubMed ID: 10937709
[TBL] [Abstract][Full Text] [Related]
60. Molecular mechanisms underlying the activation and regulation of the alpha 1B-adrenergic receptor.
Cotecchia S; Scheer A; Fanelli F; Costa T
Biochem Soc Trans; 1996 Nov; 24(4):959-63. PubMed ID: 8968492
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
